Comment from BioinvestGPT

Summary: BioinvestGPT ApS, a biotechnology company, supports the FDA's drug repurposing efforts by proposing a mechanism-driven AI tool (BVCT) to provide independent, prospective predictions of drug effects in new indications. They argue that this tool can help the Agency identify and prioritize candidates for unmet medical needs, particularly where no commercial sponsor exists to provide evidence.